Lipum AB Logo

Lipum AB

Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.

LIPUM | ST

Overview

Corporate Details

ISIN(s):
SE0015660899 (+1 more)
LEI:
549300V7JL0004BHBD93
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a first-in-class humanized antibody that offers a unique mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum's primary goal is to address unmet medical needs and improve the quality of life for patients suffering from conditions such as rheumatoid arthritis (RA). The company has successfully completed its First-in-Human (FIH) Phase I clinical trial for SOL-116, with findings supporting continued development towards a potential new therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipum AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-14 Peter Hovstadius Other Sell 2,000 28,260.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 22,770.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 21,030.00 SEK

Peer Companies

Company Country Ticker View
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden BIOVIC
BIOVIE INC. Logo
Develops drug therapies for Alzheimer's, Parkinson's, and advanced liver diseases by targeting inflammation.
United States of America BIVI
BioXcel Therapeutics, Inc. Logo
AI-driven biopharma developing treatments for neuroscience and immuno-oncology.
United States of America BTAI
Black Diamond Therapeutics, Inc. Logo
Develops precision oncology drugs targeting mutation families in lung and brain cancers.
United States of America BDTX
BL Pharmtech Corp. Logo
Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.
South Korea 065170
BOIRON Logo
Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.
France BOI
Bon Natural Life Ltd Logo
Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.
United States of America BON
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina BSNL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America BBOT

Talk to a Data Expert

Have a question? We'll get back to you promptly.